The influence of age and other prognostic factors associated with survival of ovarian immature teratoma — A study of 1307 patients

Gynecologic Oncology

Volumn 142, Issue 3, 2016, Pages 446-451

  Chan, John K ^a   Gardner, Austin B ^b   Chan, Joshua E ^a   Guan, Andrew ^a   Alshak, Mark ^a   Kapp, Daniel S ^c  

^a PALO ALTO MEDICAL FOUNDATION   (United States)

^b PALO ALTO MEDICAL FOUNDATION RESEARCH INSTITUTE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Germ cell tumor; Immature teratoma; Ovarian cancer; Prognostic factors

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HYSTERECTOMY; INFANT; MAJOR CLINICAL STUDY; OVARIAN IMMATURE TERATOMA; OVARIECTOMY; OVARY TERATOMA; PRIORITY JOURNAL; ASIAN AMERICAN; CANCER REGISTRY; CANCER STAGING; CAUCASIAN; EPIDEMIOLOGY; ETHNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; TERATOMA; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASIAN AMERICANS; CHILD; CHILD, PRESCHOOL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; TERATOMA; UNITED STATES; YOUNG ADULT;

EID: 84978873799     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.07.001     Document Type: Article

References (31)

1. [1] Tewari, K., Cappuccini, F., Disaia, P.J., Berman, M.L., Manetta, A., Kohler, M.F., Malignant germ cell tumors of the ovary. Obstet. Gynecol. 95:1 (2000), 128–133.
2. [2] Chan, J.K., Tewari, K.S., Waller, S., Cheung, M.K., Shin, J.Y., Osann, K., et al. The influence of conservative surgical practices for malignant ovarian germ cell tumors. J. Surg. Oncol. 98:2 (2008), 111–116.
3. [3] Pashankar, F., Hale, J.P., Dang, H., Krailo, M., Brady, W.E., Rodriguez-Galindo, C., et al. Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. Cancer, 2015.
4. [4] Patterson, D.M., Murugaesu, N., Holden, L., Seckl, M.J., Rustin, G.J., A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int. J. Gynecol. Cancer: Official Journal of the International Gynecological Cancer Society 18:1 (2008), 43–50.
5. [5] Mangili, G., Scarfone, G., Gadducci, A., Sigismondi, C., Ferrandina, G., Scibilia, G., et al. Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). Gynecol. Oncol. 119:1 (2010), 48–52.
6. [6] Rogers, P.C., Olson, T.A., Cullen, J.W., Billmire, D.F., Marina, N., Rescorla, F., et al. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: a Pediatric Intergroup Study–Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 22:17 (2004), 3563–3569.
7. [7] NCNN Clinical Practice Guidelines in Oncology [cited 2015].
8. [8] Hale, G.A., Marina, N.M., Jones-Wallace, D., Greenwald, C.A., Jenkins, J.J., Rao, B.N., et al. Late effects of treatment for germ cell tumors during childhood and adolescence. J. Pediatr. Hematol. Oncol. 21:2 (1999), 115–122.
9. [9] Billmire, D.F., Cullen, J.W., Rescorla, F.J., Davis, M., Schlatter, M.G., Olson, T.A., et al. Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 32:5 (2014), 465–470.
10. [10] van Buuren, S., Groothuis-Oudshoorn, K., Mice: multivariate imputation by chained equations in R. J. Stat. Softw. 45:3 (2011), 1–67.
11. [11] van Buuren, S., Multiple imputation of discrete and continuous data by fully conditional specification. Stat. Methods Med. Res. 16:3 (2007), 219–242.
12. [12] van Buuren, S., Flexible Imputation of Missing Data. 2012, Boca Raton, FL.
13. [13] Barnard, J.R.D., Small-sample degrees of freedom with multiple imputation. Biometrika 86 (1999), 948–955.
14. [14] Smith, H.O., Berwick, M., Verschraegen, C.F., Wiggins, C., Lansing, L., Muller, C.Y., et al. Incidence and survival rates for female malignant germ cell tumors. Obstet. Gynecol. 107:5 (2006), 1075–1085.
15. [15] Bryant, C.S., Kumar, S., Shah, J.P., Mahdi, H., Ali-Fehmi, R., Munkarah, A.R., et al. Racial disparities in survival among patients with germ cell tumors of the ovary—United States. Gynecol. Oncol. 114:3 (2009), 437–441.
16. [16] Lopes, L.F., Macedo, C.R., Aguiar Sdos, S., Barreto, J.H., Martins, G.E., Sonaglio, V., et al. Lowered cisplatin dose and no bleomycin in the treatment of pediatric germ cell tumors: results of the GCT-99 protocol from the Brazilian Germ Cell Pediatric Oncology Cooperative Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 34:6 (2016), 603–610.
17. [17] State and County QuickFacts: U.S. Census Bureau. Available from: http://quickfacts.census.gov/qfd/states/00000.html.
18. [18] Smith, H.O., Qualls, C.R., Prairie, B.A., Padilla, L.A., Rayburn, W.F., Key, C.R., Trends in gestational choriocarcinoma: a 27-year perspective. Obstet. Gynecol. 102:5 Pt 1 (2003), 978–987.
19. [19] Ghazarian, A.A., Trabert, B., Graubard, B.I., Schwartz, S.M., Altekruse, S.F., McGlynn, K.A., Incidence of testicular germ cell tumors among US men by census region. Cancer 121:23 (2015), 4181–4189.
20. [20] McGlynn, K.A., Cook, M.B., Etiologic factors in testicular germ-cell tumors. Future Oncol. 5:9 (2009), 1389–1402.
21. [21] Skakkebaek, N.E., Testicular dysgenesis syndrome. Horm. Res., 60(Suppl. 3), 2003, 49.
22. [22] Cook, M.B., Trabert, B., McGlynn, K.A., Organochlorine compounds and testicular dysgenesis syndrome: human data. Int. J. Androl. 34:4 Pt 2 (2011), e68–e84 (discussion e-5).
23. [23] Baranzelli, M.C., Bouffet, E., Quintana, E., Portas, M., Thyss, A., Patte, C., Non-seminomatous ovarian germ cell tumors in children. Eur. J. Cancer 36:3 (2000), 376–383.
24. [24] Mann, J.R., Raafat, F., Robinson, K., Imeson, J., Gornall, P., Sokal, M., et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 18:22 (2000), 3809–3818.
25. [25] Norris, H.J., Zirkin, H.J., Benson, W.L., Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer 37:5 (1976), 2359–2372.
26. [26] O'Connor, D.M., Norris, H.J., The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int. J. Gynecol. Pathol.: Official Journal of the International Society of Gynecological Pathologists 13:4 (1994), 283–289.
27. [27] Tyler, C.W. Jr., Lee, N.C., Robboy, S.J., Kurman, R.J., Paris, A.L., Wingo, P.A., et al. The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists?. Am. J. Obstet. Gynecol. 164:1 Pt 1 (1991), 65–70.
28. [28] Hankey, B.F., Ries, L.A., Edwards, B.K., The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol. Biomarker. Prev.: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 8:12 (1999), 1117–1121.
29. [29] Frazier, A.L., Hale, J.P., Rodriguez-Galindo, C., Dang, H., Olson, T., Murray, M.J., et al. Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33:2 (2015), 195–201.
30. [30] Collinson, K., Murray, M.J., Orsi, N.M., Cummings, M., Shipley, J., Joffe, J.K., et al. Age-related biological features of germ cell tumors. Genes Chromosom. Cancer 53:3 (2014), 215–227.
31. [31] Kraggerud, S.M., Hoei-Hansen, C.E., Alagaratnam, S., Skotheim, R.I., Abeler, V.M., Rajpert-De Meyts, E., et al. Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis. Endocr. Rev. 34:3 (2013), 339–376.